Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials

Data source: Bayside Health Alfred Powertrials list of active trials
Last updated: 3 September 2026

Clear filter
682 clinical trials found
Clinical trials

PFOX

PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial (NCT03737409)

Currently recruiting

Pilot SEMA-Obesity

Effects of Semaglutide on Myocardial Energetics in People with Obesity: A Pilot Prospective Mechanistic Study (Trial Not Registered)

A pilot study investigating the acute effects of semaglutide on the heart
Coming soon

Pilot WLM

A phase 2 randomised, open-label trial of maintenance of weight loss with alternate-weekly incretin medication dosing (ACTRN12625000609459)

Currently recruiting

PIPE-791-201

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE-791 in Subjects with Idiopathic Pulmonary Fibrosis (NCT07284459)

This is a Phase 2, randomized, double-blind, placebo-controlled, global multicenter study to evaluate the efficacy, safety, tolerability, and PK of PIPE-791 in subjects with a clinical diagnosis of IPF with or without background antifibrotic treatment.
Coming soon

PIPOZA

Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated with Pirtobrutinib after Previous Treatment with Zanubrutinib (NCT06812715)

This is a multicentre single-arm prospective phase II trial evaluating pirtobrutinib in the treatment of relapsed/refractory (R/R) Chronic Lymphocytic Leukaemia (CLL) patients who have previously received zanubrutinib, and to specifically evaluate Bruton Tyrosine Kinase (BTK) mutational status (clonal dynamics) before, during and after treatment with pirtobrutinib.
Currently recruiting

PiVET-ED

A prospective, randomized, single-blinded, sham controlled study of Pelvic Vein Embolization (PVE) for treatment of erectile dysfunction (ED) (ACTRN12620001023943)

Currently recruiting

PoCeMR

Development of Clinical Utility for Point of Care MRI (Trial Not Registered)

Currently recruiting

POIESIS

A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib (NCT06479135)

Currently recruiting

POLARIS-3

A Single-Arm Registrational Phase III Study of Olverembatinib in the Treatment of Patients with SDH-Deficient Gastrointestinal Stromal Tumor [POLARIS-3] (NCT06640361)

Currently recruiting

POLARIS1

A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined with Chemotherapy Versus Imatinib Combined with Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). (NCT06051409)

Currently recruiting

PORTHOS Study

A Prospective angiOtensin vs. noRadrenaline Trial for Hypotension management to reduce length Of hospital stay in Cardiac Surgery (the PORTHOS study) (ACTRN12623000848606p)

Currently recruiting

Portico IDE

Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial (PORTICO)

The PORTICO pivotal IDE trial is a prospective, multi-center, randomized, controlled clinical investigation study designed to evaluate the safety and effectiveness of the SJM Portico Transcatheter Heart Valve and Delivery Systems (Portico) via transfemoral and alternative delivery methods in high-risk and extreme-risk patients.

No longer recruiting

Portico NG

Portico NG - Evaluation of the Navitor Transcatheter Aortic Valve in High and Extreme Risk Patients with Symptomatic Severe Aortic Stenosis

The primary objective of this clinical study is to evaluate the acute safety and effectiveness of the Navitor Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak at 30 days. The results from this study will be descriptively compared to the data from the first-generation Portico Transcatheter Aortic Heart Valve and commercially available TAVI devices studied in the same patient population (e.g. high and extreme surgical risk).

No longer recruiting

POST-ETERNAL

Extending the time window for Tenecteplase by Effective RecanalizatioN of bAsilar artery occLusion in patients with POSTerior circulation stroke (NCT05105633)

Currently recruiting

POTAT

A Pilot Study of Post Operative Iron Infusion for the Treatment of Anaemia in trauma Patients (ACTRN12624000410550)

No longer recruiting

PRAX-628-212

An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures (NCT06908356)

The main purpose of this study is to see how well PRAX-628 works in treating focal onset seizures (the type of seizure that starts when only one area of the brain starts firing uncontrolled electrical signals) and primary generalised tonic-clonic seizures (the type of seizure that occurs when uncontrolled electrical activity affects the entire brain from the start). Additional purposes of this study are to see how safe PRAX-628 is and how the body processes (pharmacokinetics, PK) it. In this study, all participants will receive PRAX-628 30 mg (3 x 10 mg capsules) once daily (QD) for 8 weeks.
Currently recruiting

PREDICT

PREdiction and Diagnosis using Imaging and Clinical biomarkers Trial in Traumatic Brain Injury (ACTRN12620001360909)

No longer recruiting

PrEEN

Prospective assessment of the effects of Exclusive Enteral Nutrition on inflammation, epithelial integrity and body composition in patients with Crohn’s disease (ACTRN12625000357459)

Currently recruiting

PREVAIL

Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies (NCT05142722)

No longer recruiting

PREVENT-NEURO

Prophylaxis against early ventilator-associated infections to reduce mortality in mechanically ventilated ICU patients with acute brain injuries (NCT06819592)

The PREVENT-NEURO study will test the hypothesis that among adults with acute brain injuries receiving invasive mechanical ventilation in the ICU (participants), one dose of 2g of intravenous ceftriaxone administered as soon as practical after endotracheal intubation (intervention), compared to a matched placebo (comparator), reduces 90-day mortality (primary outcome).
Coming soon
23 24 25 26 27